NASDAQ:BCYC Bicycle Therapeutics (BCYC) Stock Price, News & Analysis → “The Stock Market’s Bull Run is Far from Over” -Barrons (From Vertical Research Advisory) (Ad) Free BCYC Stock Alerts $24.90 +0.35 (+1.43%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$24.09▼$24.9750-Day Range$16.75▼$26.1052-Week Range$12.54▼$28.91Volume205,069 shsAverage Volume360,465 shsMarket Capitalization$748.00 millionP/E RatioN/ADividend YieldN/APrice Target$47.88 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Bicycle Therapeutics alerts: Email Address Bicycle Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.88 Rating ScoreUpside/Downside92.3% Upside$47.88 Price TargetShort InterestHealthy8.52% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.31Based on 3 Articles This WeekInsider TradingSelling Shares$209,125 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($5.20) to ($5.82) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.21 out of 5 starsMedical Sector546th out of 938 stocksPharmaceutical Preparations Industry246th out of 422 stocks 3.4 Analyst's Opinion Consensus RatingBicycle Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $47.88, Bicycle Therapeutics has a forecasted upside of 92.3% from its current price of $24.90.Amount of Analyst CoverageBicycle Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted8.52% of the outstanding shares of Bicycle Therapeutics have been sold short.Short Interest Ratio / Days to CoverBicycle Therapeutics has a short interest ratio ("days to cover") of 7.1.Change versus previous monthShort interest in Bicycle Therapeutics has recently decreased by 7.25%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldBicycle Therapeutics does not currently pay a dividend.Dividend GrowthBicycle Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BCYC. Previous Next 1.8 News and Social Media Coverage News SentimentBicycle Therapeutics has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Bicycle Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for BCYC on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows4 people have added Bicycle Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Bicycle Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $209,125.00 in company stock.Percentage Held by Insiders10.20% of the stock of Bicycle Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions86.15% of the stock of Bicycle Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Bicycle Therapeutics are expected to decrease in the coming year, from ($5.20) to ($5.82) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bicycle Therapeutics is -4.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bicycle Therapeutics is -4.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBicycle Therapeutics has a P/B Ratio of 2.02. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingAI Cracks Open Largest Untapped Energy Reserve on EarthThis orb represents the largest untapped energy source in the world… And although this energy resource is unknown by 99% of the public… It makes gas, coal, oil, wind, hydropower, solar, fusion… ]click here to watch a free presentation where I reveal all the details of this lucrative opportunit About Bicycle Therapeutics Stock (NASDAQ:BCYC)Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II and phase II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. The company has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.Read More BCYC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BCYC Stock News HeadlinesMarch 27, 2024 | msn.comTrek’s New Wahoo Path Hybrid Kids Line Helps Create Life-Long Bicycle RidersMarch 21, 2024 | bizjournals.comRed Bicycle coffee shop in The Nations temporarily closed due to fire damageMarch 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 19, 2024 | msn.comTake a cool bike ride at Icicle BicycleMarch 17, 2024 | msn.comTrek Bicycle in Little Rock holds grand reopening after March 31 tornado destroyed original locationMarch 16, 2024 | msn.comRiverbend Bicycle Club, Clinton, hosts annual rideMarch 16, 2024 | finance.yahoo.comBCYC Apr 2024 12.500 callMarch 16, 2024 | finance.yahoo.comBCYC Apr 2024 22.500 callMarch 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 16, 2024 | finance.yahoo.comBCYC Apr 2024 20.000 putMarch 12, 2024 | seekingalpha.comBicycle: 2nd Half Of 2024 Data Could Provide Significant Inflection PointMarch 6, 2024 | bizjournals.comThe Downtube Bicycle Works to close after more than 50 yearsMarch 5, 2024 | businesswire.comBicycle Therapeutics to Present at the AACR Annual Meeting 2024February 28, 2024 | businesswire.comBicycle Therapeutics to Participate in Upcoming Investor ConferencesFebruary 23, 2024 | finance.yahoo.comEarnings Update: Bicycle Therapeutics plc (NASDAQ:BCYC) Just Reported Its Yearly Results And Analysts Are Updating Their ForecastsFebruary 21, 2024 | finance.yahoo.comBicycle Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues LagFebruary 21, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Bicycle Therapeutics (BCYC) and Teladoc (TDOC)February 21, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: NeoGenomics (NEO) and Bicycle Therapeutics (BCYC)February 21, 2024 | msn.comBicycle Therapeutics Is Worried About This – Should You Be Worried Too?February 21, 2024 | markets.businessinsider.comThe Analyst Landscape: 4 Takes On Bicycle TherapeuticsFebruary 20, 2024 | msn.comBicycle Therapeutics GAAP EPS of -$1.16 beats by $0.15, revenue of $5.33M misses by $1.55MFebruary 20, 2024 | finance.yahoo.comBicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial ResultsFebruary 20, 2024 | businesswire.comBicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial ResultsFebruary 17, 2024 | finance.yahoo.comBCYC Mar 2024 7.500 putFebruary 17, 2024 | finance.yahoo.comBCYC Jun 2024 7.500 putFebruary 9, 2024 | forbes.comBicycle Association Seeks Government Support To Halt ‘Continuum Of Decline’ As U.K. Cycle Sales Slump To 39-Year LowFebruary 4, 2024 | omaha.comRoute for Bicycle Ride Across Nebraska is announcedSee More Headlines Receive BCYC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bicycle Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/20/2024Today3/28/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:BCYC CUSIPN/A CIK1761612 Webwww.bicycletherapeutics.com Phone441223261503FaxN/AEmployees284Year FoundedN/APrice Target and Rating Average Stock Price Target$47.88 High Stock Price Target$65.00 Low Stock Price Target$32.00 Potential Upside/Downside+93.0%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($5.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-180,660,000.00 Net Margins-669.72% Pretax Margin-664.32% Return on Equity-57.80% Return on Assets-34.14% Debt Debt-to-Equity Ratio0.08 Current Ratio8.08 Quick Ratio8.08 Sales & Book Value Annual Sales$26.98 million Price / Sales27.61 Cash FlowN/A Price / Cash FlowN/A Book Value$12.35 per share Price / Book2.01Miscellaneous Outstanding Shares30,040,000Free Float26,979,000Market Cap$744.99 million OptionableOptionable Beta0.90 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesDr. Kevin Lee M.B.A. (Age 56)Ph.D., CEO & Executive Director Comp: $1.31MSir Gregory Paul Winter CBE (Age 73)FMedsci, FRS, HonFRCP, HonFTSE, Co-Founder & Non-Executive Director Comp: $55kMr. Alistair Milnes (Age 50)Chief Operating Officer Comp: $796.09kDr. Michael Skynner B.sc. Ph.d. (Age 54)Ph.D., Chief Technology Officer Comp: $881.01kDr. Christian HeinisScientific FounderMs. Alethia Rene Young (Age 45)Chief Financial Officer Mr. Travis ThompsonSenior VP, Chief Accounting Officer & Principal Accounting OfficerDr. Nicholas Keen Ph.D. (Age 55)Chief Scientific Officer Mr. Zafar QadirGeneral CounselMr. David E. Borah CFASenior Vice President of Capital Markets & Corporate CommunicationsMore ExecutivesKey CompetitorsZymeworksNYSE:ZYMEAstria TherapeuticsNASDAQ:ATXSPharming GroupNASDAQ:PHAREnliven TherapeuticsNASDAQ:ELVNLongboard PharmaceuticalsNASDAQ:LBPHView All CompetitorsInsiders & InstitutionsPNC Financial Services Group Inc.Bought 7,560 shares on 3/22/2024Ownership: 0.025%Price T Rowe Associates Inc. MDSold 316,216 shares on 2/16/2024Ownership: 0.922%Citadel Advisors LLCSold 13,900 shares on 2/15/2024Ownership: 0.000%Horizon Kinetics Asset Management LLCSold 604 shares on 2/15/2024Ownership: 0.048%Virtus ETF Advisers LLCBought 2,467 shares on 2/15/2024Ownership: 0.021%View All Insider TransactionsView All Institutional Transactions BCYC Stock Analysis - Frequently Asked Questions Should I buy or sell Bicycle Therapeutics stock right now? 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bicycle Therapeutics in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" BCYC shares. View BCYC analyst ratings or view top-rated stocks. What is Bicycle Therapeutics' stock price target for 2024? 8 Wall Street research analysts have issued twelve-month price objectives for Bicycle Therapeutics' shares. Their BCYC share price targets range from $32.00 to $65.00. On average, they anticipate the company's stock price to reach $47.88 in the next year. This suggests a possible upside of 92.3% from the stock's current price. View analysts price targets for BCYC or view top-rated stocks among Wall Street analysts. How have BCYC shares performed in 2024? Bicycle Therapeutics' stock was trading at $18.08 at the start of the year. Since then, BCYC shares have increased by 37.7% and is now trading at $24.90. View the best growth stocks for 2024 here. When is Bicycle Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our BCYC earnings forecast. How were Bicycle Therapeutics' earnings last quarter? Bicycle Therapeutics plc (NASDAQ:BCYC) released its earnings results on Tuesday, February, 20th. The company reported ($1.16) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.23) by $0.07. The firm earned $5.33 million during the quarter, compared to analysts' expectations of $11.68 million. Bicycle Therapeutics had a negative trailing twelve-month return on equity of 57.80% and a negative net margin of 669.72%. What ETFs hold Bicycle Therapeutics' stock? ETFs with the largest weight of Bicycle Therapeutics (NASDAQ:BCYC) stock in their portfolio include Horizon Kinetics Medical ETF (MEDX), What other stocks do shareholders of Bicycle Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Bicycle Therapeutics investors own include Aldeyra Therapeutics (ALDX), AVEO Pharmaceuticals (AVEO), Fulcrum Therapeutics (FULC), Mersana Therapeutics (MRSN), AbbVie (ABBV), Adverum Biotechnologies (ADVM), Agenus (AGEN), Applied Genetic Technologies (AGTC), Akero Therapeutics (AKRO) and Alector (ALEC). When did Bicycle Therapeutics IPO? Bicycle Therapeutics (BCYC) raised $64 million in an IPO on Thursday, May 23rd 2019. The company issued 4,300,000 shares at $14.00-$16.00 per share. Goldman Sachs, Jefferies and Piper Jaffray acted as the underwriters for the IPO and Canaccord Genuity was co-manager. Who are Bicycle Therapeutics' major shareholders? Bicycle Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include First Light Asset Management LLC (5.16%), Armistice Capital LLC (5.11%), Westfield Capital Management Co. LP (3.05%), Verition Fund Management LLC (2.47%), Platinum Investment Management Ltd. (1.21%) and Parkman Healthcare Partners LLC (1.04%). Insiders that own company stock include Alistair Milnes, Kate Bingham, Kevin Lee, Lee Kalowski, Michael Skynner, Nicholas Keen, Nigel Crockett, Pierre Legault, Stephen B Alexander and Travis Alvin Thompson. View institutional ownership trends. How do I buy shares of Bicycle Therapeutics? Shares of BCYC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BCYC) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bicycle Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.